Gilead Joins Growingly Crowded Protein Degradation Field with Nurix Therapeutics Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 6 (Table of Contents)
Published: 26 Jun-2019
DOI: 10.3833/pdr.v2019.i6.2437 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing its recent deal spree, Gilead Sciences has partnered with Nurix Therapeutics to discover, develop and commercialise a pipeline of targeted protein degradation drugs for the treatment of cancer and other challenging diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS